JAMESTOWN
U.S. real estate investment and management company Jamestown , most notably known for projects like Chelsea Market in New York, today announced it has acquired Rotterdam’s historic Groot Handelsgebouw, its first large format acquisition in Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191220005035/en/
The 122,000-square meter (approximately 1.3 million square foot) historic structure, located in the heart of Rotterdam next to the Central Station and 20 minutes from Schiphol airport, is emblematic of the city’s redevelopment after World War II. The building will now become a symbol of the innovation economy. Built in 1953 to help fulfil an acute need for office space Groot Handelsgebouw has become one of the largest mixed-use buildings in the Netherlands housing more than 450 businesses. Jamestown acquired the building from an investment vehicle managed by real estate private equity firm HighBrook Investors for a purchase price of €289 million. HighBrook had previously acquired the asset in July 2018 for approximately €169 million through an off-market public-to-private transaction involving the legacy Dutch listed company (EuroNext: GROHA).
“Groot Handelsgebouw is at the heart of Rotterdam’s history of growth and regeneration; we hope to continue that legacy with a new chapter through creating a hub for the new innovation economy,” said Michael Phillips, President of Jamestown.
Jamestown is a design-focused real estate company whose mission is to transform iconic spaces into innovation hubs and community centers. Its retail, local community, and mixed-use projects include Chelsea Market and Industry City in New York, Ghirardelli Square in San Francisco, Ponce City Market in Atlanta, and The Innovation and Design Building in Boston. Groot Handelsgebouw fits this diverse portfolio of adaptive reuse projects and is the first transaction led by the company’s new European team. Their Netherland’s asset management group is based in Amsterdam out of the historic bicycle factory A Factorij, which Jamestown entered into a partnership on in 2018.
HighBrook was advised on the transaction by Jones Day and Loyens & Loeff as well as its Asset Manager, Equity Estate. Jamestown was advised by Greenberg Traurig.
About Jamestown
Jamestown, LP was established in 1983 as an investment and management company focused on income-producing real estate in the United States. Jamestown companies employ approximately 450 people worldwide with headquarters in Atlanta, Georgia, and Cologne, Germany. The company has offices in Amsterdam, Bogotá, Boston, Los Angeles, New York, and San Francisco.
Since its founding, Jamestown has executed transactions in excess of $35 billion. As of 30 September 2019, the company has assets under management of $11.5 billion. Capital sources with a long term investment horizon are institutional investors, retail investors, and separate accounts.
As well as the traditional functions of a real estate management company, Jamestown possesses internal expertise that adds value to all aspects of the real estate business. Its in-house capabilities in Development & Construction, Architecture & Design, Sustainability, Retail Leasing, Creative & Marketing, and Food & Beverage curation, Jamestown maximizes value throughout an asset’s ownership period. See also www.jamestownlp.com .
About HighBrook Investors
HighBrook Investors is a private equity real estate manager that specializes in sourcing and identifying unique opportunities for value investing across market cycles. We utilize our collective experience investing in private, public, domestic, and developed international markets to identify situational opportunities across property types at optimal stages of the investment cycle. The firm was founded in 2010 and operates through its main offices in New York and London.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191220005035/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom